BiotechTV

BiotechTV - News

Science EN ↓ 429 episodes

This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.

Author

BiotechTV

Episodes

Barclays Miami: Barclays' Senior Biotech Analyst Ellie Merle shares her take on biotech and thoughts on companies she covers that have been in the news 10.03.2026 11:16

She discusses uniQure, Moderna, BridgeBio, Gossamer Bio and more.

Barclays Miami: Janux's Founder & CEO David Campbell shares his thoughts on the company's PSMA x CD3 masked T-cell engager and discusses next steps. Plus, a CD19 for autoimmune 10.03.2026 11:03

He shares highlights from data announced at the end of the year, and what Janux has learned about the program's dosing and safety mitigation profile. Also, why he has his sights set on the FcRn market when he thinks about the company's CD19.

Barclays Miami: Teva CEO Richard Francis talks about the company's emphasis on developing innovative medicines - including two recent financial deals to speed up development of IL-15 and TL1A 10.03.2026 9:20

He discusses the company's third year in a row of revenue growth, and the new products that have helped Teva get there. Plus, a potential near-term approval for a monthly dosed schizophrenia product, and the lates on IL-15 and TL1A.

Barclays Miami: Latigo Bio aims to have a best-in-class Nav1.8 - a new class of medicines for pain that is the biotech sector's answer to the challenges that are presented by opioids 10.03.2026 7:34

CEO Nima Farzan explains the science behind Nav1.8, why he believes Latigo's asset could be best in class, and the status of the company's development program.

Barclays Miami: Arvinas will have an update next week for its LRRK2 targeting PROTAC for Parkinson's. The new CEO previews that and talks other targets they are working on 10.03.2026 8:10

Randy Teel updates us on effectors to find a commercialization partner for the ER degrading PROTAC that is in front of FDA right now with a June 5 decision date scheduled. Plus, discussing programs targeting KRAS, BCL6, polyQ-AR and more.

Barclays Miami: Electra Therapeutics has taken a novel approach to target Signal Regulatory Proteins (SIRPs). It's in a pivotal for its first indication right now 10.03.2026 6:13

President and CEO Kathy Dong describes the function of SIRPs and how Electra is targeting them with antibodies. Plus, an overview of the company's privotal program against secondary Hemophagocytic Lymphohistiocytosis (sHLH).

Barclays Miami: enGene is looking to have pivotal data and to file for its non-viral delivered gene therapy for bladder cancer this year 10.03.2026 5:55

CEO Ron Cooper describes why you need an alternative to virally delivered products for indications like bladder cancer. Plus, previewing a data update in the spring and 12 month data by the end of the year.

Barclays Miami: Barclays' Chair and Co-Head of Global Biopharma Investment Banking Jim Birchenough shares his take on the sector, M&A, and the IPO environment 10.03.2026 8:13

He believes that the sector's fundamentals are strong and that M&A, which played a central role in boosting biotech last year, can keep up in 2026. Plus, he believes there is a good supply of quality IPOs in the queue that can meet demand that has been there for a while.

Quell Tx believes that restoring immune balance rather than entirely depleting immune cells is key for many autoimmune conditions - its CAR-Treg initiated a phase 1/2 in RA & Systemic Sclerosis today 03.03.2026 23:31

CEO Iain McGill describes the "Chill, not Kill" approach that Quell is taking with its Treg platform, which integrates a FOXP3 phenotype lock in addition to the CAR. Plus, an update on the company's liver transplant study, a program that he says will need a partner to move forward.

Protagonist Therapeutics has two medicines in front of FDA right now - we discuss the expertise in peptide based drug development that has enabled them to get to this point 20.02.2026 25:56

CEO Dinesh Patel and Chief Discovery Officer Ashok Bhandari walk us through the company's R&D expertise, and we discuss programs covering IL-23, IL-17, a hepcidin mimetic, and obesity medicines.

Cambridge, UK based Arecor uses formulation and development expertise to improve the profile of medicines - leveraging this, the company believes it has its own best in class insulin 19.02.2026 25:30

CEO Sarah Howell discusses three key aspects of the business: helping with reformulation, its own proprietary insulin products, and developing oral peptides like GLPs.

NewLimit is using epigenetic reprogramming to bring cells back to a younger and healthier state, thus tackling age related disease 19.02.2026 11:24

Co-Founder & President Jacob Kimmel describes the science behind how this works, and the enormous amount of work that goes into choosing which transcription factors to target. The company is currently in IND enabling studies.

Gordian Biotechnology announced that it will be using its unique large-scale in vivo screening process to help Pfizer look for new targets against obesity 18.02.2026 10:14

Co-Founder & CSO Martin Borch Jensen describes the deal and walks us through Gordian's process that enables it to do a multiplicity of in vivo screening in months that previously would have taken years.

Cambridge, UK based Microbiotica announced results from a phase 1b trial of its microbiome treatment MB310 in ulcerative colitis showing a 63% remission rate 18.02.2026 11:45

CEO Tim Sharpington and CMO Robert Tansley walk us through the treatment, which contains a defined consortium of eight live gut commensal bacterial strains, and the data.

Ocular Therapeutix Chair & CEO Pravin Dugel discusses the result of today's SOL-1 phase 3 superiority trial of AXPAXLI vs EYLEA in wet AMD 17.02.2026 13:20

The study showed that AXPAXLI has superior maintenance of visual acuity at Week 36 vs EYLEA. Dr. Dugel discusses what he believes the significance of this is, and delves into durability data going out to 52 weeks.

Oxford based Infinitopes raised an additional $15.4M in a second closing of its seed round to bring the total raised to $35.1M. It will have clinical data on its cancer vaccine by the end of the year 17.02.2026 15:35

Co-Founder & CEO Jonathan Kwok describes the company's platform, which helps it identify highly expressed and immunogenic tumor antigens, and how the lead program for oesophageal cancer will have data by the end of 2026.

From Oxford: Carlo Rinaldi's team has received two grants from Oxford-Harrington Rare Disease Centre to develop treatments for Spinal-bulbar muscular atrophy (SBMA) and Friedreich's ataxia 17.02.2026 9:35

He describes his work in these diseases and how Oxford-Harrington has provided funding and advice that has been valuable beyond the feedback he typically receives in an academic setting.

From Oxford: Professor Matthew Wood describes the Oxford-Harrington Rare Disease Centre, a transatlantic effort to accelerate drug development for rare diseases 17.02.2026 21:04

He highlights the centre's Scholars program, which researchers anywhere can apply for and funds ten new drug development programs each year. Plus the centre's accelerator program and plans for a rare disease investment fund. He also discusses how regulatory changes at places like MHRA can help the rare disease community.

Biotech CEOs discuss the state of the industry, what is needed to compete globally, the importance of having a patient-centric approach, and more 13.02.2026 42:26

MassBio President & CEO Kendalle Burlin O'Connell moderates a discussion with Aurora Therapeutics CEO Ed Kaye and DaCapo Brainscience CEO Leslie Williams about being biotech leaders during this volatile time for the industry. They stress that a key to success is that everyone in the industry work together towards shared goals.

Analyst Thursdays: Mizuho Senior Biotech Analyst Graig Suvannavejh shares his take on three key biotech trials that are scheduled to read out soon, and one that recently happened 12.02.2026 18:55

He discusses upcoming readouts for IDEAYA Biosciences, Ocular Therapeutix (how it might affect EyePoint), and Palvella Therapeutics. Plus, his take on the recent Corvus atopic dermatitis data.

Upstream Bio's CEO Rand Sutherland discusses today's severe asthma data for verekitug, a TSLP receptor antagonist 11.02.2026 13:13

He describes top-line data the company saw across three different doses, next steps, and also shares an update on additional indications of chronic rhinosinusitis with nasal polyps and COPD it is being developed for.

Corvus Pharma CEO Richard Miller fields follow-up questions about last week's atopic dermatitis data for the ITK inhibitor soquelitinib 28.01.2026 27:18

He discusses learnings about durability, dosing, biomarkers, and more for this first-in-class target.

Analysts Thursdays: Clear Street Senior Biotech Analyst Kaveri Pohlman shares her take on biotech for 2026 and discusses her top picks 22.01.2026 16:46

She discusses Arrivent Biopharma, Oruka Therapeutics, Jade Biosciences, Zura Bio, and Pavella Therapeutics.

SF Healthcare Week: Perceptive Advisors' Joe Edelman, one of the top investors in biotech, shares his investment philosophy and his take on the sector heading into 2026 17.01.2026 11:28

He talks about Perceptive's investment philosophy, his take on the year ahead, areas he thinks are over and under hyped, and thoughts on China. Plus, the rationale for a few of his top holdings.

SF Healthcare Week: Cytokinetics CEO Robert Blum discusses the approval and impending launch of the cardiomyopathy therapy MYQORZO 16.01.2026 11:55

He discussed the REMS, launch plans, market opportunity, payors, and the metrics that the company will offer publicly over time. Plus, previewing a key new data readout that will be coming in the second quarter of this year.